

Cover Story
Free
As administrations change, cancer research stands in an unusually strong position, NCI Acting Director Douglas Lowy said in an interview with The Cancer Letter.
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- No need for a speculum? A new era of HPV screening
- Most Favored Nation drug pricing could put China on top
- Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line














